YAZGAN, S. C. Et Al. 2024. The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (177Lu)-PSMA-617. Prostate .

YAZGAN, S. C., Yekeduz, E., ARAZ, M., BÖLEK, H., KÜÇÜK, N. Ö., & ÜRÜN, Y., (2024). The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (177Lu)-PSMA-617. Prostate .

YAZGAN, SATI Et Al. "The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (177Lu)-PSMA-617," Prostate , 2024

YAZGAN, SATI C. Et Al. "The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (177Lu)-PSMA-617." Prostate , 2024

YAZGAN, S. C. Et Al. (2024) . "The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (177Lu)-PSMA-617." Prostate .

@article{article, author={SATI COŞKUN YAZGAN Et Al. }, title={The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (177Lu)-PSMA-617}, journal={Prostate}, year=2024}